GENB
Generate Biomedicines, Inc.
NASDAQ · Financial Services · Asset Management · US
$14.46
−8.33%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -50.9%
- EBITDA
- -28.3%
- EPS
- +56.2%
Three-year CAGR
- Revenue
- +55.9%
- EBITDA
- -27.4%
- EBIT
- -19.4%
- Net income
- -16.9%
- EPS
- —
- Free cash flow
- -68.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026